Gentamicin treatment results in significant changes in lysosomal morphology and enzyme activity in renal tubular epithelium both in vivo and in vitro. In this study, cultured human proximal tubular cells (PTC) were treated with gentamicin (0, 0.01, 0.1, and 1.0 mg/ml) for 3, 7, 10 and 14 days, and the endocytotic activity, pH, and membrane fragility of the lysosomal system were examined. Fluorescein isothiocyanate-labeled dextran (FITC-dextran) was used to estimate endocytotic activity and intralysosomal pH. The fragility of isolated lysosomes was estimated by the release of N-acetyl-beta-glucosaminidase (NAG, EC3.2.1.30) into the medium. Gentamicin content was measured and correlated with the changes seen in lysosomal function. Gentamicin treatment caused a slight decrease in the rate with which human PTC accumulated FITC-dextran and a slight increase in intralysosomal pH. Treatment of human PTC with NH4Cl, a lysosomotropic compound, significantly increased the lysosomal pH; the NH4Cl-induced increase in the lysosomal pH of gentamicin-treated PTC, however, was not significantly different from control (0 mg gentamicin/ml). Lysosomes isolated from human PTC cultures released NAG upon incubation for 60 min at 37 degrees. There was no significant effect on the fragility of lysosomes isolated from cultures exposed to gentamicin for less than or equal to 7 days. Significantly increased fragility was seen, however, after 10 days of treatment with 1.0 mg gentamicin/ml and especially after a 14-day exposure to 0.01, 0.1, and 1.0 mg gentamicin/ml. Human PTC accumulated 0.47, 2.05 and 10.30 micrograms gentamicin/mg protein with 10 days of exposure to 0.01, 0.1 and 1.0 mg gentamicin/ml medium respectively. Gentamicin treatment associated with increased numbers of morphologically altered lysosomes, i.e. myeloid bodies, did not affect significantly the endocytotic activity and pH of lysosomes in cultured human PTC. Prolonged exposure (14 days) of human PTC to gentamicin, however, did increase the fragility of lysosomes after isolation. The increased numbers of morphologically altered lysosomes with increased fragility were not associated with any significant in vitro cell death. Therefore, it would appear that these lysosomal alterations are not directly responsible for the in vivo nephrotoxicity.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0006-2952(89)90098-1 | DOI Listing |
J Epidemiol Glob Health
January 2025
Centre of Environment and Population Health, School of Medicine and Dentistry, Griffith University, Nathan, QLD, 4111, Australia.
The incidence of thyroid cancer has shown marked increases globally over recent decades. This study investigated how the incidence of papillary thyroid carcinoma (PTC) subtypes and World Health Organisation (WHO) endocrine tumour classification changes have affected overall thyroid cancer incidence recorded in Australia. Using incidence data from the Australian Institute of Health and Welfare cancer registry (spanning 1982 to 2019), this descriptive epidemiological study employed joinpoint regression analysis to assess temporal trends in thyroid carcinoma incidence, focusing on PTC.
View Article and Find Full Text PDFProbl Endokrinol (Mosk)
March 2024
Background: KI-67 (MKI-67 in humans) is a protein able to bind to DNA which contributes to cell growth and cell proliferation. KI-67 is currently considered as a biomarker that is widely utilized as prognostic indicator for evaluating cell proliferation, diagnosing diseases, and conducting research. Several different kinds of cancer have high Ki-67 expression, which simplifying the choice of treatment for individuals with various cancer types.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
January 2025
Department of Ultrasound Diagnosis, Affiliated Kunshan Hospital of Jiangsu University, Kunshan, China.
Objectives: This study aims to develop a nomogram to predict high-volume (> 5) lymph node metastases (HVLNM) in papillary thyroid carcinoma concomitant with Hashimoto's thyroiditis by combining ultrasound with clinicopathologic data.
Materials And Methods: The study reviewed 187 patients diagnosed with papillary thyroid cancer (PTC) concomitant with Hashimoto's thyroiditis from the First People's Hospital of Kunshan between March 2018 and December 2022. These patients underwent preoperative ultrasound and postoperative examinations.
Lancet Neurol
February 2025
Department of Neurology, International University of Health and Welfare, Narita, Japan.
Background: Evidence from preclinical studies suggests that IL-6 signalling has the potential to modulate immunopathogenic mechanisms upstream of autoantibody effector mechanisms in patients with generalised myasthenia gravis. We aimed to assess the safety and efficacy of satralizumab, a humanised monoclonal antibody targeting the IL-6 receptor, in patients with generalised myasthenia gravis.
Methods: LUMINESCE was a randomised, double-blind, placebo-controlled, multicentre, phase 3 study at 105 sites, including hospitals and clinics, globally.
Int J Mol Sci
January 2025
Department of Electrical and Computer Engineering, College of Electrical and Computer Engineering, National Yang Ming Chiao Tung University, Hsinchu 300, Taiwan.
Bisphenol A (BPA) is a prevalent environmental contaminant found in plastics and known for its endocrine-disrupting properties, posing risks to both human health and the environment. Despite its widespread presence, the impact of BPA on papillary thyroid cancer (PTC) progression, especially under realistic environmental conditions, is not well understood. This study examined the effects of BPA on PTC using a 3D thyroid papillary tumor spheroid model, which better mimicked the complex interactions within human tissues compared to traditional 2D models.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!